Recombinant short TNF-BD protein from smallpox virus is pharmacologically active in an experimental septic shock model

Tumor necrosis factor (TNF) is one among the key cytokines that mediate the immune system to protect humans against viral infections. Throughout evolution, anthropogenic Variola virus (VARV) has developed effective mechanisms to overcome human defense reactions. The viral genome encodes soluble prot...

Full description

Saved in:
Bibliographic Details
Main Authors: I. P. Gileva, S. N. Yakubitskiy, I. V. Kolosova, S. N. Shchelkunov
Format: Article
Language:English
Published: Siberian Branch of the Russian Academy of Sciences, Federal Research Center Institute of Cytology and Genetics, The Vavilov Society of Geneticists and Breeders 2020-05-01
Series:Вавиловский журнал генетики и селекции
Subjects:
Online Access:https://vavilov.elpub.ru/jour/article/view/2588
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832575094394716160
author I. P. Gileva
S. N. Yakubitskiy
I. V. Kolosova
S. N. Shchelkunov
author_facet I. P. Gileva
S. N. Yakubitskiy
I. V. Kolosova
S. N. Shchelkunov
author_sort I. P. Gileva
collection DOAJ
description Tumor necrosis factor (TNF) is one among the key cytokines that mediate the immune system to protect humans against viral infections. Throughout evolution, anthropogenic Variola virus (VARV) has developed effective mechanisms to overcome human defense reactions. The viral genome encodes soluble proteins imitating the structure of cellular cytokine receptors. These proteins compete with cellular receptors for cytokine binding, thus blocking the antiviral immune response. In particular, the G2R gene of VARV encodes the TNF decoy receptor, VARV-CrmB protein. This protein consists of N-ended TNF-biding (TNF-BD) and C-ended chemokine binding (Ch-BD) domains. Recombinant VARV-CrmB protein has been produced in insect cells using molecular cloning methods and its TNF neutralizing activity has been shown in vitro and in vivo. To decrease the immunogenicity of this protein, a recombinant plasmid coding for shortened TNF-BD protein of VARV in Escherichia coli cells has been constructed. Using the method of immobilized metal affinity chromatography, recombinant TNF-BD protein corresponding to the TNF-biding domain of VARV-CrmB protein was purified from E. coli cells. The therapeutic potential of TNF-BD was studied using an experimental model of LPS-induced septic shock. After septic shock induction, several doses of recombinant TNF-BD were injected and the mortality of experimental animals was observed during 7 days. All mice not injected with TNF-BD had been dead by day 3 of the experiment, but 30, 40 and 60 % of the experimental animals, who received different TNF-BD doses, survived in a dose-dependent manner. Data obtained demonstrate that recombinant TNF-BD protein is pharmacologically active in the experimental model of LPS-induced septic shock.
format Article
id doaj-art-7f73e38844824e1c9f6c57c1d0208075
institution Kabale University
issn 2500-3259
language English
publishDate 2020-05-01
publisher Siberian Branch of the Russian Academy of Sciences, Federal Research Center Institute of Cytology and Genetics, The Vavilov Society of Geneticists and Breeders
record_format Article
series Вавиловский журнал генетики и селекции
spelling doaj-art-7f73e38844824e1c9f6c57c1d02080752025-02-01T09:58:08ZengSiberian Branch of the Russian Academy of Sciences, Federal Research Center Institute of Cytology and Genetics, The Vavilov Society of Geneticists and BreedersВавиловский журнал генетики и селекции2500-32592020-05-0124323924310.18699/VJ20.6161047Recombinant short TNF-BD protein from smallpox virus is pharmacologically active in an experimental septic shock modelI. P. Gileva0S. N. Yakubitskiy1I. V. Kolosova2S. N. Shchelkunov3State Research Center of Virology and Biotechnology “Vector'’, RospotrebnadzorState Research Center of Virology and Biotechnology “Vector'’, RospotrebnadzorState Research Center of Virology and Biotechnology “Vector'’, RospotrebnadzorState Research Center of Virology and Biotechnology “Vector'’, Rospotrebnadzor; Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of SciencesTumor necrosis factor (TNF) is one among the key cytokines that mediate the immune system to protect humans against viral infections. Throughout evolution, anthropogenic Variola virus (VARV) has developed effective mechanisms to overcome human defense reactions. The viral genome encodes soluble proteins imitating the structure of cellular cytokine receptors. These proteins compete with cellular receptors for cytokine binding, thus blocking the antiviral immune response. In particular, the G2R gene of VARV encodes the TNF decoy receptor, VARV-CrmB protein. This protein consists of N-ended TNF-biding (TNF-BD) and C-ended chemokine binding (Ch-BD) domains. Recombinant VARV-CrmB protein has been produced in insect cells using molecular cloning methods and its TNF neutralizing activity has been shown in vitro and in vivo. To decrease the immunogenicity of this protein, a recombinant plasmid coding for shortened TNF-BD protein of VARV in Escherichia coli cells has been constructed. Using the method of immobilized metal affinity chromatography, recombinant TNF-BD protein corresponding to the TNF-biding domain of VARV-CrmB protein was purified from E. coli cells. The therapeutic potential of TNF-BD was studied using an experimental model of LPS-induced septic shock. After septic shock induction, several doses of recombinant TNF-BD were injected and the mortality of experimental animals was observed during 7 days. All mice not injected with TNF-BD had been dead by day 3 of the experiment, but 30, 40 and 60 % of the experimental animals, who received different TNF-BD doses, survived in a dose-dependent manner. Data obtained demonstrate that recombinant TNF-BD protein is pharmacologically active in the experimental model of LPS-induced septic shock.https://vavilov.elpub.ru/jour/article/view/2588varv-crmb proteinvariola viruslpsseptic shocktnf-biding domain
spellingShingle I. P. Gileva
S. N. Yakubitskiy
I. V. Kolosova
S. N. Shchelkunov
Recombinant short TNF-BD protein from smallpox virus is pharmacologically active in an experimental septic shock model
Вавиловский журнал генетики и селекции
varv-crmb protein
variola virus
lps
septic shock
tnf-biding domain
title Recombinant short TNF-BD protein from smallpox virus is pharmacologically active in an experimental septic shock model
title_full Recombinant short TNF-BD protein from smallpox virus is pharmacologically active in an experimental septic shock model
title_fullStr Recombinant short TNF-BD protein from smallpox virus is pharmacologically active in an experimental septic shock model
title_full_unstemmed Recombinant short TNF-BD protein from smallpox virus is pharmacologically active in an experimental septic shock model
title_short Recombinant short TNF-BD protein from smallpox virus is pharmacologically active in an experimental septic shock model
title_sort recombinant short tnf bd protein from smallpox virus is pharmacologically active in an experimental septic shock model
topic varv-crmb protein
variola virus
lps
septic shock
tnf-biding domain
url https://vavilov.elpub.ru/jour/article/view/2588
work_keys_str_mv AT ipgileva recombinantshorttnfbdproteinfromsmallpoxvirusispharmacologicallyactiveinanexperimentalsepticshockmodel
AT snyakubitskiy recombinantshorttnfbdproteinfromsmallpoxvirusispharmacologicallyactiveinanexperimentalsepticshockmodel
AT ivkolosova recombinantshorttnfbdproteinfromsmallpoxvirusispharmacologicallyactiveinanexperimentalsepticshockmodel
AT snshchelkunov recombinantshorttnfbdproteinfromsmallpoxvirusispharmacologicallyactiveinanexperimentalsepticshockmodel